0000899243-22-026421.txt : 20220720
0000899243-22-026421.hdr.sgml : 20220720
20220720180020
ACCESSION NUMBER: 0000899243-22-026421
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220718
FILED AS OF DATE: 20220720
DATE AS OF CHANGE: 20220720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: YVER ANTOINE
CENTRAL INDEX KEY: 0001861878
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40445
FILM NUMBER: 221095232
MAIL ADDRESS:
STREET 1: C/O CENTESSA PHARMACEUTICALS PLC
STREET 2: D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3FH
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Centessa Pharmaceuticals plc
CENTRAL INDEX KEY: 0001847903
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3RD FLOOR
STREET 2: 1 ASHLEY ROAD
CITY: ALTRINCHAM, CHESHIRE
STATE: X0
ZIP: WA14 2DT
BUSINESS PHONE: 44 7391 789784
MAIL ADDRESS:
STREET 1: 3RD FLOOR
STREET 2: 1 ASHLEY ROAD
CITY: ALTRINCHAM, CHESHIRE
STATE: X0
ZIP: WA14 2DT
FORMER COMPANY:
FORMER CONFORMED NAME: Centessa Pharmaceuticals Ltd
DATE OF NAME CHANGE: 20210224
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-18
0
0001847903
Centessa Pharmaceuticals plc
CNTA
0001861878
YVER ANTOINE
C/O CENTESSA PHARMACEUTICALS PLC
3RD FL., 1 ASHLEY RD, ALTRINCHAM
CHESHIRE
X0
WA14 2DT
UNITED KINGDOM
0
1
0
0
EVP & Chairman of Development
Ordinary Shares
2022-07-18
4
S
0
20000
4.8656
D
810597
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 17, 2021, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.74 to $5.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Marella Thorell, attorney-in-fact
2022-07-20